Planova 20N |
PPV |
6.0-6.5 log10TCID50
/mL (0.5% spike) |
11.4 |
NA |
Polyclonal antibody, pI 6.8 - 10 |
1 -
50 |
pH 5, 100 mM NaCl |
NA |
≥ 5.42 |
(Hongo-Hirasaki, Komuro et al.
2010) |
|
PPV
|
0.1 % single spike
|
14 ±2
|
100-200
|
mAbs, therapeutic proteins, and bi-specific antibodies (9
molecules)
|
3.1 - 13.0
|
pH 4.9 - 8.3,
various buffers with 50-300 mM NaCl
|
Yes
|
2.86 – 7.15
|
(Stuckey, Strauss et al. 2014)
|
|
|
0.1% mixed spike with 2.5% MMV
|
|
110-190
|
mAbs (6 molecules)
|
4.2 – 13.0
|
pH 4.9 - 8.3,
various buffers with 50-200 mM NaCl
|
|
3.59 – 5.19
|
|
|
PPV |
1:50 single spike |
manufacturer recommendation
~13 |
50 |
Prothrombin complex concentrate solution |
2.6 |
pH 6.5 sodium citrate buffer and 15 mM NaCl |
2 |
≥6.0 |
(Nowak, Popp et al. 2019) |
|
|
Mixed spike with CPV and MMV |
|
|
|
|
|
|
≥5.8 |
|
|
MMV |
NA |
NA |
200-400 |
23 mAbs (IgG1 and IgG2) |
NA |
pH 5.0 – 7.5 |
NA |
Approx. ≥3.9 – ≥6.9 |
(Gefroh,
Dehghani et al. 2014) |
|
MMV |
Approx. 6.0 Log10TCID50 /mL, 1%
(v/v) spike |
7.3 – 16.0 |
50 |
3 mAb molecules (IgG1), pI 7.2-9.0 |
5.0 |
pH 4.0 – 8.0, conductivity3.0-20.0 mS/cm |
15 |
4.0 - ≥5.5 |
(Strauss, Goldstein et al.
2017) |
|
|
|
2.8 |
NA |
|
|
|
|
2.9 - ≥5.0 |
|
|
MMV |
1:50 single spike |
manufacturer recommendation
~13 |
50 |
Prothrombin complex concentrate solution |
2.6 |
pH 6.5 sodium citrate buffer and 15 mM NaCl |
2 |
≥7.3 |
(Nowak, Popp et al. 2019) |
|
|
1:50 mixed spike with CPV and B19V |
2.9 |
|
|
1.7 |
|
|
≥5.7 |
|
|
CPV |
5.5 – 8.5 log10 CCID50/
0.001m2, 1:50 single spike |
manufacturer
recommendation ~13 |
50 |
Prothrombin complex
concentrate solution |
2.6 |
pH 6.5 sodium citrate buffer and 15 mM NaCl |
2 |
3.8 ± 0.7 |
(Nowak, Popp et al.
2019) |
|
|
1:50 mixed spike with MMV and B19V |
2.9 |
|
|
1.7 |
|
|
2.9 |
|
|
B19V
|
1:50 single spike
|
13
|
50
|
Prothrombin complex concentrate solution
|
1.7
|
pH 6.5 sodium citrate buffer and 15 mM NaCl
|
2
|
≥4.4
|
(Nowak, Popp et al. 2019)
(Nowak, Popp et al. 2019)
|
|
|
1:50 mixed spike with CPV and MMV |
13 |
|
|
|
|
|
≥4.3 |
|
|
|
1:50 mixed spike with CPV and MMV |
2.9 |
|
|
|
|
|
≥6.8 |
|
Viresolve Pro |
MMV |
0.1% spike |
NA |
904-1042 |
mAb |
NA |
pH 5.0,
50 mM acetate |
NA |
≥4.68 |
(Gefroh,
Dehghani et al. 2014) |
|
|
NA
|
10 - 50
|
125 - 500
|
mAb
|
5-40
|
pH 4.5, or pH 7.5,
with 0-500 mM NaCl
|
NA
|
5.20 - ≥ 6.10
|
(Chen 2014)
|
|
|
6.47-8.22 log10 copies/mL by QPCR |
NA |
NA |
8 mAbs |
NA |
NA |
NA |
3.69 - ≥5.45 |
(Gefroh,
Dehghani et al. 2014) |
|
|
NA |
NA |
NA |
mAbs |
NA |
NA |
NA |
≥4.2 |
(Miesegaes, Lute et al.
2010) |
|
|
NA |
NA |
NA |
Not specified (1 molecule) |
NA |
NA |
NA |
≥6.44 |
(Stuckey, Strauss et al.
2014) |
|
PPV |
NA |
NA |
NA |
Not specified (2 molecules) |
NA |
NA |
NA |
5.72
- ≥6.96 |
(Stuckey, Strauss et al.
2014) |
Virosart CPV |
PPV |
NA |
NA |
NA |
Not specified (1 molecule) |
NA |
NA |
NA |
6.00 |
(Stuckey, Strauss et al.
2014) |
Planova BioEx |
MMV |
Approx. 6.0
Log10TCID50 /mL, 1.0% spike |
10.0 –
49.7 |
50 |
3 mAb molecules (IgG1), pI 7.2-9.0 |
5.0 |
pH 4.0 – 8.0,
conductivity 3.0-20.0 mS/cm |
15 |
≥ 4.8 - ≥ 5.6 |
(Strauss, Goldstein et al.
2017) |
Viresolve NFP |
MMV |
0.1% spike |
NA |
904-1042 |
mAb |
NA |
pH 5.0,
50 mM acetate |
NA |
4.07 |
(Gefroh,
Dehghani et al. 2014) |
Various small virus retentive filters (Planova 20N, Planova BioEX,
Viresolve Pro, Viresolve NFP, Ultipor DV20, Pegasus SV4, Pegasus Prime,
Virosart CPV, Virosart HF, Virosart HC) |
CPV |
1:50 mixed spike with
MMV and PPV |
Manufacturer recommendation |
28.5-50 |
Prothrombin
complex concentrate solution |
1.7 |
pH 6.5 sodium citrate buffer and 15
mM NaCl |
No pause |
0.7 - ≥6.9 |
(Nowak,
Popp et al. 2019) |
|
|
1:100 mixed spike with MMV |
|
126-900 |
Human serum albumin
solution |
4.0 |
pH 5.5 MES buffer and 225 mM NaCl |
|
0.1 - ≥6.8 |
|
|
MMV |
1:50 mixed spike with CPV and PPV |
Manufacturer recommendation |
28.5-50 |
Prothrombin complex concentrate solution |
1.7 |
pH 6.5
sodium citrate buffer and 15 mM NaCl |
No pause |
3.5 - ≥7.0 |
|
|
|
1:100 mixed spike with CPV |
|
126-900 |
Human serum albumin
solution |
4.0 |
pH 5.5 MES buffer and 225 mM NaCl |
|
2.5 - ≥7.2 |
|
|
PPV |
1:50 mixed spike with CPV and MMV |
Manufacturer recommendation |
28.5-50 |
Prothrombin complex concentrate solution |
1.7 |
pH 6.5
sodium citrate buffer and 15 mM NaCl |
No pause |
≥3.9 - ≥5.7 |
|
Various nominal pore size 15-20 nm filters (Planova 15N, Planova 20N,
Planova BioEX, Pall DV20, Virosart HC, Viresolve NFP, Viresolve VPro) |
parvoviruses (B19V, BPV, CPV, MMV, PPV) |
NA |
4-50 |
0-1200 |
Plasma
proteins (Inhibitors, immunoglobulins, coagulation factors, and others) |
NA |
pH 4.8-8.4, conductivity 0.48-48 mS/cm |
NA |
Approx. 3.9 - ≥ 8.9
when intended for parvovirus removal; Approx. 1.5 to ≥7.5 if not
specifically targeted for parvovirus |
(Roth, Dichtelmüller et al.
2020) |
Not specified
|
MMV
|
0.5 – 1.0% spike
|
9-14
|
200-2500 g/m2
|
mAb
>100 data points
|
7-17
|
pH 6.7-7.1, salt 0-150 mM
|
NA
|
>4
|
(Chen 2014)
|
Not Specified (3 commercial small virus filters) |
MMV |
5.33-7.60 ×
106 PFU/mL |
Various pressure reduction schemes |
20 -
325 |
mAb (IgG1), pI 8.9 |
10 |
25 mM acetate, 175mM NaCl, pH 5.2 |
Various schemes |
3.1 - ≥ 6.6 |
(LaCasse,
Lute et al. 2016) |